Skip to main content
Delfa

← All trials/NCT07297589

EPIC-CT

RecruitingPhase 3

Epicardial Cardiac Fat-CT (EPIC-CT)

Epicardial Cardiac Fat Comparative Trial

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

136

Study population

Cardiovascular disease

Eligibility highlights

•EF ≥50%

Primary endpoint

•Epicardial fat

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07297589
Org study IDR-2025-1001-087

Timeline

Milestones

Study first posted2025-12-22actual
Study start2025-12-30actual
Last update posted2026-01-02actual
Primary completion2027-01estimated (month precision)
Study completion2027-03estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Cardiovascular disease

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Criteria for the fourth definition of acute myocardial infarction with and without ST-segment elevation.
-Diagnosed with type 2 diabetes.
-Initial serum high-sensitivity CRP value > 2.0 mg/L.
-Clinically obese.
-LVEF >50%.

Exclusion criteria

•Patients who have recently received immunosuppressive therapy
•Patients with a history of ischemic heart disease
•Known allergy to any of the medications used
•Use of any of the study drugs more than 6 months prior to randomization
•Patients experiencing diabetic ketoacidosis
•Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors)
•Pregnant women
•Patients with a history or current diagnosis of cancer
•Patients with documented active infections, such as pneumonia or urinary tract infections
•Patients with pancreatitis

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Cardiovascular outcomes
1
Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Cardiovascular outcomes

1 endpoint
Secondary/protocol endpoint

Major adverse cardiovascular events (MACE)

Time frame:12 months

4-point MACE

composite event, event

componentsHeart-failure hospitalization, Myocardial infarction (any), Cardiovascular death, Stroke (any)

Weight & body composition

2 endpoints
Primary/protocol endpoint

Epicardial fat

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in body weight

Time frame:12 months

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in fasting glucose and HbA1c

Time frame:12 months

change from baseline, improvement

componentsFasting glucose, change, HbA1c, change

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Change in LDL

Time frame:12 months

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.